Crescent Biopharma (CBIO) EBITDA (2013 - 2026)
Crescent Biopharma (CBIO) reported EBITDA of -$23.3 million for Q1 2026, down 53.7% year-over-year from -$50.3 million in Q1 2025, and up 74.8% on a QoQ basis from -$92.4 million in Q4 2025.
Crescent Biopharma (CBIO) has 14 years of EBITDA data on file, last reported at -$23.3 million in Q1 2026.
- Quarterly EBITDA fell 53.7% year-over-year to -$23.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$162.1 million (down 252.31% YoY) and the FY2025 annual result came in at -$153.9 million, down 761.6% from the prior year.
- EBITDA advanced to -$23.3 million in Q1 2026 per CBIO's latest filing, from -$92.4 million in the prior quarter.
- Across five years, EBITDA topped out at -$2.6 million in Q3 2024 and bottomed at -$92.4 million in Q4 2025.
- The 5-year median for EBITDA is -$11.1 million (2024), against an average of -$18.0 million.
- The widest annual swing landed in 2024, when EBITDA jumped 73.19%; it then tumbled 835.27% in 2025.
- Tracing CBIO's EBITDA over 5 years: stood at -$10.6 million in 2022, then increased by 9.71% to -$9.6 million in 2023, then tumbled by 86.29% to -$17.9 million in 2024, then sank by 417.14% to -$92.4 million in 2025, then surged by 74.8% to -$23.3 million in 2026.
- Per Business Quant, the three latest CBIO EBITDA figures stand at -$23.3 million (Q1 2026), -$92.4 million (Q4 2025), and -$24.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - | -23.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -23.28 Mn |
| Dec 31, 2025 | -92.40 Mn |
| Sep 30, 2025 | -24.61 Mn |
| Jun 30, 2025 | -21.79 Mn |
| Mar 31, 2025 | -15.15 Mn |
| Dec 31, 2024 | -17.87 Mn |
| Sep 30, 2024 | -2.63 Mn |
| Jun 30, 2024 | -10.36 Mn |
| Mar 31, 2024 | -11.12 Mn |
| Dec 31, 2023 | -9.59 Mn |
| Sep 30, 2023 | -9.81 Mn |
| Jun 30, 2023 | -8.93 Mn |
| Mar 31, 2023 | -10.94 Mn |
| Dec 31, 2022 | -10.62 Mn |
| Sep 30, 2022 | -8.77 Mn |
| Jun 30, 2022 | -13.35 Mn |
| Mar 31, 2022 | -14.66 Mn |
| Dec 31, 2021 | -17.43 Mn |
| Sep 30, 2021 | -17.34 Mn |
| Jun 30, 2021 | -14.40 Mn |
| Mar 31, 2021 | -14.28 Mn |
| Dec 31, 2020 | -15.57 Mn |
| Sep 30, 2020 | -13.73 Mn |
| Jun 30, 2020 | -14.11 Mn |
| Mar 31, 2020 | -8.11 Mn |
| Dec 31, 2019 | -15.34 Mn |
| Sep 30, 2019 | -14.11 Mn |
| Jun 30, 2019 | -16.82 Mn |
| Mar 31, 2019 | -15.13 Mn |
| Dec 31, 2018 | -14.96 Mn |
| Sep 30, 2018 | -12.52 Mn |
| Jun 30, 2018 | -12.15 Mn |
| Mar 31, 2018 | -12.15 Mn |
| Dec 31, 2017 | -9.54 Mn |
| Sep 30, 2017 | -8.18 Mn |
| Jun 30, 2017 | -8.24 Mn |
| Mar 31, 2017 | -7.97 Mn |
| Dec 31, 2016 | -8.36 Mn |
| Sep 30, 2016 | -7.89 Mn |
| Jun 30, 2016 | -8.09 Mn |
| Mar 31, 2016 | -7.58 Mn |
| Dec 31, 2015 | -8.89 Mn |
| Sep 30, 2015 | -7.17 Mn |
| Jun 30, 2015 | 10.39 Mn |
| Mar 31, 2015 | -7.11 Mn |
| Dec 31, 2014 | -7.40 Mn |
| Sep 30, 2014 | -6.70 Mn |
| Jun 30, 2014 | 8.06 Mn |
| Mar 31, 2014 | -5.11 Mn |
| Dec 31, 2013 | -3.87 Mn |
| Sep 30, 2013 | -3.70 Mn |
| Jun 30, 2013 | -3.50 Mn |
| Mar 31, 2013 | 458,722.00 |